301 related articles for article (PubMed ID: 33941482)
21. Electroporation and genetic supply of Cas9 increase the generation efficiency of CRISPR/Cas9 knock-in alleles in C57BL/6J mouse zygotes.
Alghadban S; Bouchareb A; Hinch R; Hernandez-Pliego P; Biggs D; Preece C; Davies B
Sci Rep; 2020 Oct; 10(1):17912. PubMed ID: 33087834
[TBL] [Abstract][Full Text] [Related]
22. CRISPR-READI: Efficient Generation of Knockin Mice by CRISPR RNP Electroporation and AAV Donor Infection.
Chen S; Sun S; Moonen D; Lee C; Lee AY; Schaffer DV; He L
Cell Rep; 2019 Jun; 27(13):3780-3789.e4. PubMed ID: 31242412
[TBL] [Abstract][Full Text] [Related]
23. Drug target validation in primary human natural killer cells using CRISPR RNP.
Rautela J; Surgenor E; Huntington ND
J Leukoc Biol; 2020 Oct; 108(4):1397-1408. PubMed ID: 33463756
[TBL] [Abstract][Full Text] [Related]
24. Delivery of Plasmid DNA by Ionizable Lipid Nanoparticles to Induce CAR Expression in T Cells.
Prazeres PHDM; Ferreira H; Costa PAC; da Silva W; Alves MT; Padilla M; Thatte A; Santos AK; Lobo AO; Sabino A; Del Puerto HL; Mitchell MJ; Guimaraes PPG
Int J Nanomedicine; 2023; 18():5891-5904. PubMed ID: 37873551
[TBL] [Abstract][Full Text] [Related]
25. Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection.
Liang X; Potter J; Kumar S; Zou Y; Quintanilla R; Sridharan M; Carte J; Chen W; Roark N; Ranganathan S; Ravinder N; Chesnut JD
J Biotechnol; 2015 Aug; 208():44-53. PubMed ID: 26003884
[TBL] [Abstract][Full Text] [Related]
26. Non-viral transfection technologies for next-generation therapeutic T cell engineering.
Raes L; De Smedt SC; Raemdonck K; Braeckmans K
Biotechnol Adv; 2021; 49():107760. PubMed ID: 33932532
[TBL] [Abstract][Full Text] [Related]
27. Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system.
Hajifathali A; Lasemi MV; Mehravar M; Moshari MR; Alizadeh AM; Roshandel E
Hematol Transfus Cell Ther; 2024; 46(1):58-66. PubMed ID: 37451978
[TBL] [Abstract][Full Text] [Related]
28. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
[TBL] [Abstract][Full Text] [Related]
29. Gene Targeting of HPV18 E6 and E7 Synchronously by Nonviral Transfection of CRISPR/Cas9 System in Cervical Cancer.
Ling K; Yang L; Yang N; Chen M; Wang Y; Liang S; Li Y; Jiang L; Yan P; Liang Z
Hum Gene Ther; 2020 Mar; 31(5-6):297-308. PubMed ID: 31989837
[TBL] [Abstract][Full Text] [Related]
30. Delivery of the Cas9/sgRNA Ribonucleoprotein Complex in Immortalized and Primary Cells via Virus-like Particles ("Nanoblades").
Mangeot PE; Guiguettaz L; Sohier TJM; Ricci EP
J Vis Exp; 2021 Mar; (169):. PubMed ID: 33871447
[TBL] [Abstract][Full Text] [Related]
31. One-step generation of modular CAR-T cells with AAV-Cpf1.
Dai X; Park JJ; Du Y; Kim HR; Wang G; Errami Y; Chen S
Nat Methods; 2019 Mar; 16(3):247-254. PubMed ID: 30804551
[TBL] [Abstract][Full Text] [Related]
32. A ribonucleoprotein transfection strategy for CRISPR/Cas9-mediated gene editing and single cell cloning in rainbow trout cells.
Zoppo M; Okoniewski N; Pantelyushin S; Vom Berg J; Schirmer K
Cell Biosci; 2021 Jun; 11(1):103. PubMed ID: 34082820
[TBL] [Abstract][Full Text] [Related]
33. Improvement of baculovirus as protein expression vector and as biopesticide by CRISPR/Cas9 editing.
Pazmiño-Ibarra V; Mengual-Martí A; Targovnik AM; Herrero S
Biotechnol Bioeng; 2019 Nov; 116(11):2823-2833. PubMed ID: 31403180
[TBL] [Abstract][Full Text] [Related]
34. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.
Simon B; Harrer DC; Schuler-Thurner B; Schaft N; Schuler G; Dörrie J; Uslu U
Exp Dermatol; 2018 Jul; 27(7):769-778. PubMed ID: 29704887
[TBL] [Abstract][Full Text] [Related]
35. Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells.
Cappabianca D; Li J; Zheng Y; Tran C; Kasparek K; Mendez P; Thu R; Maures T; Capitini CM; Deans R; Saha K
Front Bioeng Biotechnol; 2024; 12():1379900. PubMed ID: 38882639
[TBL] [Abstract][Full Text] [Related]
36. Efficient mouse genome engineering by CRISPR-EZ technology.
Modzelewski AJ; Chen S; Willis BJ; Lloyd KCK; Wood JA; He L
Nat Protoc; 2018 Jun; 13(6):1253-1274. PubMed ID: 29748649
[TBL] [Abstract][Full Text] [Related]
37. Highly Efficient Transfection of Human Primary T Lymphocytes Using Droplet-Enabled Mechanoporation.
Joo B; Hur J; Kim GB; Yun SG; Chung AJ
ACS Nano; 2021 Aug; 15(8):12888-12898. PubMed ID: 34142817
[TBL] [Abstract][Full Text] [Related]
38. In Vitro-Transcribed (IVT)-mRNA CAR Therapy Development.
Miliotou AN; Papadopoulou LC
Methods Mol Biol; 2020; 2086():87-117. PubMed ID: 31707670
[TBL] [Abstract][Full Text] [Related]
39. mRNA-based CAR T-cells manufactured by miniaturized two-step electroporation produce selective cytotoxicity toward target cancer cells.
Jayasooriya V; Ringwelski B; Dorsam G; Nawarathna D
Lab Chip; 2021 Sep; 21(19):3748-3761. PubMed ID: 34585697
[TBL] [Abstract][Full Text] [Related]
40. Ribonucleoprotein Transfection for CRISPR/Cas9-Mediated Gene Knockout in Primary T Cells.
Oh SA; Seki A; Rutz S
Curr Protoc Immunol; 2019 Feb; 124(1):e69. PubMed ID: 30334617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
